465 related articles for article (PubMed ID: 2089856)
21. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns JS; Rudnick MR; Cohen RM
Clin Nephrol; 1992 May; 37(5):264-7. PubMed ID: 1606777
[TBL] [Abstract][Full Text] [Related]
22. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
23. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
25. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
26. [Therapy of renal anemia with recombinant human erythropoietin].
Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients].
Jacquot C; Berthelot JM; Chiappini-Judith D; Ferragu-Haguet M; Lefebvre A; Masselot JP; Moynot A; Frydman MO; Peterlongo F
Nephrologie; 1990; 11(1):11-6. PubMed ID: 2374641
[TBL] [Abstract][Full Text] [Related]
28. Management of anemia in erythropoietin-resistant hemodialysis patients.
Dar Santos AE; Shalansky KF; Jastrzebski JP
Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
30. [Personal experience with the use of human recombinant erythropoietin in the treatment of anemia in children with chronic renal insufficiency].
Podracká L; Sasinka M; Roland R; Böör A
Cesk Pediatr; 1992 May; 47(5):268-71. PubMed ID: 1638649
[TBL] [Abstract][Full Text] [Related]
31. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
32. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
[TBL] [Abstract][Full Text] [Related]
34. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
[TBL] [Abstract][Full Text] [Related]
36. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
Hotta T; Ogawa H; Saito A; Ito A
Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
[TBL] [Abstract][Full Text] [Related]
37. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
38. [The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin].
Borrego FJ; Miguel JL; Zamorano A; Muñoz J; Bajo A; López-Revuelta K; Sánchez Sicilia L
Med Clin (Barc); 1991 Nov; 97(18):687-92. PubMed ID: 1770818
[TBL] [Abstract][Full Text] [Related]
39. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
[TBL] [Abstract][Full Text] [Related]
40. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration.
Lubrich-Birkner I; Schollmeyer P; Steinhauer HB
Adv Perit Dial; 1990; 6():302-7. PubMed ID: 1982833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
